Frazier Life Sciences Management’s Dyne Therapeutics DYN Stock Holding History

Frazier Life Sciences Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$57.2M	Hold	3,153,082	–	–	1.47%	16
2025 Q4	$61.7M	Buy	3,153,082 +434,977	+16%	+$8.24M	1.66%	16
2025 Q3	$34.4M	Buy	2,718,105 +1,212,121	+80%	+$13.8M	1.03%	21
2025 Q2	$14.3M	Buy	1,505,984 +62,643	+4%	+$690K	0.57%	35
2025 Q1	$15.1M	Buy	+1,443,341	New	+$20.6M	0.69%	30
2024 Q1	–	Sell	-1,184,840	Closed	-$15.8M	–	53
2023 Q4	$15.8M	Buy	+1,184,840	New	+$11.6M	0.84%	33

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Frazier Life Sciences Management's DYN Position: Q1 2026 in Review

Frazier Life Sciences Management held its Dyne Therapeutics (DYN) position steady in Q1 2026 at 3,153,082 shares worth $57.2M. The position accounts for 1.47% of the portfolio, ranked #16.

Frazier Life Sciences Management first reported a position in DYN in Q4 2023 and has held it in 6 quarters since. The position peaked at $61.7M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Frazier Life Sciences Management held 3,153,082 shares of Dyne Therapeutics worth $57.2M as of Q1 2026.
Frazier Life Sciences Management left its Dyne Therapeutics share count unchanged in Q1 2026.
Dyne Therapeutics made up 1.47% of Frazier Life Sciences Management's portfolio in Q1 2026, its #16 holding.
Frazier Life Sciences Management first reported a position in Dyne Therapeutics in Q4 2023 and has held it in 6 quarters since.
Frazier Life Sciences Management's Dyne Therapeutics position peaked at $61.7M in Q4 2025.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.